The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function
NCT ID: NCT01993485
Last Updated: 2014-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
61 participants
OBSERVATIONAL
2013-06-30
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesized that altered haemodynamics may at least partly be responsible for observed endothelial dysfunction in patients with AVS. Therefore, the aim of this study is to investigate whether the resolution of AVS by transaortic valve implacement (TAVI) affects WSS, improves endothelial dysfunction and decreases levels of circulating EMPs as markers of endothelial integrity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NCT04204915
TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics
NCT06896227
Long-Term Effects of Aortic Valve Mismatch
NCT00854698
Severe Aortic Valve Stenosis and Concomitant Coronary Artery Disease in Patients Undergoing TAVI
NCT04385459
SAfe and Fast Discharge With Acurate Valve in Low Risk tavI Patients
NCT05983458
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* screened for TAVI
* written informed consent
Exclusion Criteria
* Patients with acute infections (CRP\> 0.5 mg / dL)
* Patients with Atrial Fibrillation
* Patients with inflammatory and malignant diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klinik für Kardiologie, Pneumologie und Angiologie
Division of Cardiology, Pulmonary Diseases, Vascular Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ralf Westenfeld, MD
Role: PRINCIPAL_INVESTIGATOR
Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf
Malte Kelm, Professor
Role: STUDY_CHAIR
Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Cardiology, Pulmonary Diseases, Vascular Medicine, University Hospital Dusseldorf
Düsseldorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP TAVI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.